Digbi Health has added clinical hormone replacement therapy to its telehealth platform, allowing women to obtain GLP-1 and hormone prescriptions through one app and one clinical team. Care is personalized using genetic data, gut microbiome profiling, continuous glucose monitoring and advanced blood biomarkers, with access offered through more than 300 employers and health plans. The model tests whether consolidating metabolic and endocrine care under a single clinical interface improves outcomes and reduces fragmented digital health spend.
Key Points
- Hormone therapy and GLP-1 prescribing unified under one clinical team
- Personalization draws on genetics, microbiome, glucose and blood biomarkers
- Platform reaches 30 million people via 300+ employer plans
Longevity Analysis
Metabolic and endocrine decline in midlife rarely present as separate problems, yet they are typically managed by separate clinicians using separate data. Combining glucose dynamics, microbiome composition and hormonal status in one record improves the accuracy with which symptoms are interpreted — fatigue, weight gain and disrupted sleep are frequently attributed to the wrong origin when each signal is read in isolation. The durability of the approach will depend less on the breadth of testing than on whether consolidated access sustains adherence over the years required for metabolic and hormonal interventions to alter long-term risk.
Original published by LT Wire.